Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 27, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis Clear all

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase Powder for Oral Solution; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 28 Days and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Little Rock, Arkansas • Orange, California • Aurora, Colorado + 17 more

Conditions: Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions: Discontinuation of Pancreatic Enzyme Replacement Therapy; Drug
Lead sponsor: Indiana University; Other
Eligibility: 0 Years to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more

Conditions: Cystic Fibrosis
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase, porcine (pig) PERT; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 32
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 28 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more

Conditions: Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Omeprazole 20mg Capsule, Placebo oral capsule; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
Interventions: Pancrease MT 10.5, or MT 21, Placebo for Pancrease MT 10.5 or MT 21; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 7 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 7 more

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase, porcine PERT; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 28
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 24 more

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont

Conditions: Cystic Fibrosis
Interventions: Pancrelipase; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more

Search by objective public record fields.

Phase 2 Study to Assess the Safety and Efficacy of ANG003

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

EASY: Extended Access to Sollpura Over Years

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis